FDA Greenlights Eli Lilly’s GLP-1 Pill Amid Obesity Drug Race

The U.S. Food and Drug Administration has approved Eli Lilly’s once-daily oral GLP-1 agonist Foundayo, marking a significant milestone in the obesity treatment landscape. This approval positions Foundayo as the second FDA-sanctioned oral obesity pill, directly challenging Novo Nordisk’s pill formulation of Wegovy. Analysts project the GLP-1 market could surpass $100 billion globally by 2030, with oral formulations expected to capture a substantial share due to improved patient convenience. Foundayo’s approval follows a phase 3 trial showing an average weight loss of 15% over 72 weeks, comparable to injectable counterparts. Eli Lilly’s shares edged higher on the news, reflecting investor confidence in its expanding obesity portfolio. The competitive dynamics echo broader trends in pharmaceutical innovation, where convenience and efficacy drive market share. Meanwhile, geopolitical tensions in nuclear policy discussions have indirectly influenced healthcare supply chains, underscoring the interconnected nature of global markets. As the obesity drug race heats up, the focus shifts to pricing strategies and insurance coverage, which could determine the long-term success of these therapies.